[Big coffee gathers in Wuhan East Lake, bright spots] 132+615 pharmaceutical colleagues talk about the frontier of medicine and seek the future of the industry!

The first Wuhan East Lake biomedical Innovation and Development Forum

On July 7-9, the First Wuhan East Lake Biomedical Innovation and Development Forum, co-sponsored by Hongren Pharmaceutical and Tongji Medical College of Huazhong University of Science and Technology, was successfully held at Crowne Plaza Wuhan Optics Valley Bio-City. 132 special guests from scientific research institutes, pharmaceutical enterprises, investment institutions and clinical institutions attended the meeting and made reports and round-table exchanges, and the number of participants reached 615.

The forum was jointly guided by the Professional Committee of Pharmaceutical BioAnalysis of Chinese Pharmaceutical Society, the Chamber of Commerce of Pharmaceutical Industry of All-China Federation of Industry and Commerce, the Office of Wuhan Leading Group for Investment Promotion and Investment Promotion and Wuhan National Biological Industry Base Construction Service Center, with the theme of "Foreseeing the Frontier of Medicine and Meeting the future of Industry". Focusing on hot topics related to different subcategories of drugs, such as chemical innovative drugs, polypeptide drugs, oncolytic viruses and AAV drugs, protein and antibody drugs, cell therapy drugs, generic and improved innovative drugs, ADC drugs and vaccine drugs, Covering the pharmaceutical industry development frontier and trend, new drug research and development project and pipeline layout, non-clinical pharmacokinetics and safety evaluation to clinical research, biological analysis and detection, data management and statistical analysis and other professional topics.

Jiangcheng Sheng, quality Chu Fenghua, refers to the Yangtze River sigh with regret, gather medical colleagues. The first Wuhan East Lake Biomedical Innovation and Development Forum set off a new wave of integration, unity and win-win of pharmaceutical research and development forces in Wuhan.

The opening ceremony of the main forum was presided over by Yu Yanfei, director of the Industrial Department of Wuhan National Biological Industry Base Construction Service Center. Zhang Dingyu, member of the Party Group, Deputy director and Chief of public health of Hubei Provincial Health Commission, Zhang Quan, Executive Deputy Director of Wuhan Investment Promotion Leading Group Office, Lv Donghong, technical Deputy director of the Medical Industry Chamber of Commerce, All-China Federation of Industry and Commerce, and Jiang Hongliang, professor of Huazhong University of Science and Technology and founder of Hongren Medicine, attended the opening ceremony and delivered speeches.

The speakers elaborated from the dimensions of industrial policy, science and education talents, talent introduction, public health, new drug research and development, clinical research, generic drug consistency evaluation and development, and industry association empowerment. The forum, held in Wuhan and radiating across the country, aims to build a platform for communication and cooperation among pharmaceutical colleagues, promote interaction and communication among biomedical enterprises, research institutes, CRO companies and clinical institutions, improve the effective integration and utilization of clinical research and drug R&D service resources, and improve the R&D and industrialization capabilities of drug R&D enterprises. Accelerate the progress of drug research and development and the listing process, and promote the innovation and development of China's pharmaceutical industry.

During the forum, in response to the call and proposal of colleagues, leaders, experts, entrepreneurs, partners and others visited and guided the company in batches, learned about the development of various technology platforms of the company, and affirmed and praised the achievements made by the company in the field of clinical bioanalysis and non-clinical pharmacokinetic research subdivision technical services for 12 years.